Coronavirus 2 is a new enveloped RNA coronavirus, first reported in Wuhan, China. The virus neurological tendencies are well established in literature and through clinical experience. Despite being a relatively rare disease, during the COVID-19 pandemic, there was a rise in the incidence of ATM worldwide. The pathophysiology behind this rise is still not well understood. Here, we present a 65 years old male with COVID-19 associated ATM. He presented with lower extremities sensorimotor weakness for 1 day. His serum microbiology was negative. During hospitalization, the patient developed urinary retention and abdominal obstruction. The patient was given 1 mg of solu-medrol IV for five days once per day, 42 mg of disflatyl twice per day, and he received IV immunoglobulins once per day for two days.
COVID-19; Acute transverse myelitis; SARS-CoV-2
A Fallatah A, Adam AM, Fallata AA. COVID-19-Associated Acute Transverse Myelitis (ATM): A Case Report. J Neurol Neurosurg Spine. 2021; 5(1): 1020.
